October 21, 2019
Brandon May
This article is part of MPR‘s coverage of the CHEST 2019 meeting, taking place in New Orleans, LA. Our staff will report on medical research related to asthma, COPD, critical care medicine, and more conducted by experts in the field. Check back regularly for more news from CHEST 2019.
NEW ORLEANS – Twice-daily ensifentrine was associated with improvements in several symptoms of chronic obstructive pulmonary disease (COPD), including breathlessness, chest symptoms, cough and sputum, and shortness of breath, according to research presented at CHEST 2019, held October 19 to 23, 2019, in New Orleans, Louisiana.
During a 4-week study, a total of 303 patients with moderate to severe COPD (mean age, 63 years) received either placebo or twice-daily ensifentrine at doses of 0.75mg, 1.5mg, 3.0mg, and 6.0mg. Researchers evaluated changes from baseline to 4 weeks in COPD-related symptoms. Symptoms were assessed using the Evaluating-Respiratory Symptoms (E-RS), Transition Dyspnea Index (TDI), and patient global assessment of change (PGAC). The primary end point was peak forced expiratory volume in 1 second; all ensifentrine doses were statistically significant vs placebo (differences of 118-193mL; P <.001 for all).
Clinically meaningful improvements in the E-RS total score during week 4 were greater with all ensifentrine doses vs placebo (0.75mg: -3.40; 1.5mg: -2.93; 3.0mg: -2.41; 6.0mg: -2.70; all P <.05). There were also greater improvements in symptoms of breathlessness (from -1.26 to -1.51), chest (from -0.67 to 1.12), and cough and sputum (from -0.47 to −0.73) in the ensifentrine group (all P <.05).
Ensifentrine was also associated with clinically relevant improvements in TDI (≥1.0) at week 4 that were superior to placebo (differences, 1.50, 2.13, 1.75, and 1.38; P <.05 for all). In addition, greater improvements in PGAC were also observed at week 4 (differences, 0.47, 0.44, 0.44, and 0.45; P <.01 for all).
“Patients who received ensifentrine also felt that their breathing as assessed by PGAC improved significantly compared with those who received placebo,” the researchers reported.
Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.
Reference
Rickard K, Rheault T, Maurer B, Singh D. Unique dual phosphodiesterase 3/4 inhibitor, ensifentrine, significantly improves COPD symptoms including dyspnea. Presented at: CHEST 2019; October 19-23, 2019; New Orleans, LA. Abstract 450.
Brandon May
This article is part of MPR‘s coverage of the CHEST 2019 meeting, taking place in New Orleans, LA. Our staff will report on medical research related to asthma, COPD, critical care medicine, and more conducted by experts in the field. Check back regularly for more news from CHEST 2019.
NEW ORLEANS – Twice-daily ensifentrine was associated with improvements in several symptoms of chronic obstructive pulmonary disease (COPD), including breathlessness, chest symptoms, cough and sputum, and shortness of breath, according to research presented at CHEST 2019, held October 19 to 23, 2019, in New Orleans, Louisiana.
During a 4-week study, a total of 303 patients with moderate to severe COPD (mean age, 63 years) received either placebo or twice-daily ensifentrine at doses of 0.75mg, 1.5mg, 3.0mg, and 6.0mg. Researchers evaluated changes from baseline to 4 weeks in COPD-related symptoms. Symptoms were assessed using the Evaluating-Respiratory Symptoms (E-RS), Transition Dyspnea Index (TDI), and patient global assessment of change (PGAC). The primary end point was peak forced expiratory volume in 1 second; all ensifentrine doses were statistically significant vs placebo (differences of 118-193mL; P <.001 for all).
Clinically meaningful improvements in the E-RS total score during week 4 were greater with all ensifentrine doses vs placebo (0.75mg: -3.40; 1.5mg: -2.93; 3.0mg: -2.41; 6.0mg: -2.70; all P <.05). There were also greater improvements in symptoms of breathlessness (from -1.26 to -1.51), chest (from -0.67 to 1.12), and cough and sputum (from -0.47 to −0.73) in the ensifentrine group (all P <.05).
Ensifentrine was also associated with clinically relevant improvements in TDI (≥1.0) at week 4 that were superior to placebo (differences, 1.50, 2.13, 1.75, and 1.38; P <.05 for all). In addition, greater improvements in PGAC were also observed at week 4 (differences, 0.47, 0.44, 0.44, and 0.45; P <.01 for all).
“Patients who received ensifentrine also felt that their breathing as assessed by PGAC improved significantly compared with those who received placebo,” the researchers reported.
Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.
Reference
Rickard K, Rheault T, Maurer B, Singh D. Unique dual phosphodiesterase 3/4 inhibitor, ensifentrine, significantly improves COPD symptoms including dyspnea. Presented at: CHEST 2019; October 19-23, 2019; New Orleans, LA. Abstract 450.